Australia's most trusted source of pharma news
Wednesday, 20 March 2019
Lost Your Access?
Top of the Hill
Could everything old be new?
Hunt on way out of Health, what now for pharma?
PBAC calls for biosim push
Wants Health to do more in driving uptake.
Japanese pharma sets up in Oz
Search on for a GM; two drugs already in pipe.
MSD cancer drug runs short
Sole manufacturer struggling to keep up.
Look out for PBS spin change
PR boss warns pharma-friendly tone may end with election.
Novartis climbs back to top
Year begins with a return to head of PBS top ten.
New breast drug a 'huge step'
TGA approval revealed just post PBAC; will it be in time?
US pharmas set up in Aust
Two companies move to Melbourne, bringing 100-plus new jobs.
Pfizer's $432m blood problem
NBA tender opens up to new competitors.
Merck, GSK welcome new faces
CFO and exec appointments; change also at Bayer, Takeda.
Novartis ups parental leave
Global boost to time off will come to Australia.
Female execs call for flexibility
Chairs of MA's PAGE highlight career progression barrier.
Seqirus scores PBS double
Wins two of three remaining pre-election PBS berths.
GSK takes PBAC to task
Speaks out on need to recognise 'full value' of vaccines.
Head-to-head boost for Takeda
Biggest drug in trial win as Shire merger progresses.
TGA gives Brexit reassurance
Meds supply will not be impacted.
ViiV plots to upend HIV market
Radical cut to dose frequency on the horizon.
Cancer therapies added
ALL and breast cancer drugs approved.
Lilly aims I-O at lung cancer
Mid-year global filing plans for Cyramza to treat NSCLC.
Top of the Hill
Danger in 'affordability' play
Labor's focus on meds cost threatens sector unity.
Events & Conferences
© 2003 - 2019 Lush Media
Pharma in Focus
Jolly Good Design